Skip to main content
main-content

The independent medical news service

Multiple sclerosis

17-01-2019 | Multiple sclerosis | News | Article

Early aggressive treatment to delay conversion to secondary progressive MS

The findings from two studies published in JAMA show the benefits of initial disease-modifying therapy and nonmyeloablative haematopoietic stem cell transplantation in delaying conversion to secondary progressive multiple sclerosis.

Source:

JAMA 2019; 321: 153–155

JAMA 2019; 321: 165–174

JAMA 2019; 321: 175–187

10-01-2019 | Multiple sclerosis | News | Article

Rituximab shows disability benefits in patients with secondary progressive MS

Rituximab treatment may reduce and delay disability progression in patients with secondary progressive multiple sclerosis, show findings from a comprehensive real-world cohort study.

Source:

JAMA Neurol 2019; doi:10.1001/jamaneurol.2018.4239

25-10-2018 | Multiple sclerosis | News | Article

Medicinal cannabinoids show small antispastic and analgesic benefits for MS patients

The benefits of medicinal cannabinoids for the treatment of spasticity, pain and bladder dysfunction in patients with multiple sclerosis may be limited, suggests a systematic review and meta-analysis.

Source:

JAMA Network Open 2018; 1(6): e183485

JAMA Network Open 2018;1(6): e183484

13-09-2018 | Multiple sclerosis | News | Article

Fingolimod shows relapse benefits versus interferon beta-1a in paediatric multiple sclerosis

Adolescents with multiple sclerosis may experience fewer relapses if they take fingolimod versus interferon beta-1a, suggest findings from the phase III PARADIGMS trial.

Source:

New Engl J Med 2018; 379: 1017–1027

New Engl J Med 2018; 379: 1085–1086

30-08-2018 | Multiple sclerosis | Highlight | Article

Editor's pick

Ibudilast slows brain shrinkage in progressive multiple sclerosis patients

Ibudilast may slow brain atrophy in patients with progressive multiple sclerosis, show findings from a phase II study.

Source:

N Engl J Med 2018; 379: 846–855

23-08-2018 | Neurology | News | Article

Novel MS subtype suggests neurodegeneration and demyelination occur independently

Researchers have discovered a new subtype of multiple sclerosis that features neuronal loss but not demyelination of the brain’s white matter.

Source:

Lancet Neurol 2018; doi:10.1016/ S1474-4422(18)30245-X

09-08-2018 | Multiple sclerosis | News | Article

Lower risk of disability progression in primary progressive versus progressive-relapsing MS

Superimposed relapses are associated with a lower risk of confirmed disability progression among individuals with progressive-onset multiple sclerosis, suggest the results of an observational cohort study published in JAMA Neurology.

Source:

JAMA Neurol 2018; doi:10.1001/jamaneurol.2018.210

14-02-2017 | Multiple sclerosis | News | Article

Alemtuzumab compares favorably with other potent immunotherapies for MS

Researchers suggest that alemtuzumab is comparable to natalizumab for controlling multiple sclerosis activity and superior to fingolimod and interferon beta.

Source:

Lancet Neurol 2017; Advance online publication

07-02-2017 | Multiple sclerosis | News | Article

Immunosuppression and stem cell transplants achieve sustained MS remission

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation can induce long-term remission for patients with relapsing–remitting multiple sclerosis, show findings from the HALT-MS trial.

Source:

Neurology 2017; Advance online publication

26-01-2017 | Multiple sclerosis | News | Article

News in brief

Serious adverse effect with alemtuzumab reported

Researchers have highlighted the occurrence of severely exacerbated central nervous system inflammation in two patients taking alemtuzumab for multiple sclerosis.

04-01-2017 | Multiple sclerosis | News | Article

Editor's pick

Ocrelizumab shows promise in primary progressive and relapsing–remitting MS

Phase 3 trial results have shown the benefits of ocrelizumab for reducing disability progression in patients with primary progressive multiple sclerosis and disease activity in patients with the relapsing–remitting disease subtype.

Source:

N Engl J Med 2016; Advance online publication

08-12-2016 | Multiple sclerosis | News | Article

Newborn vitamin D status linked to future MS risk

Babies born with low levels of vitamin D may be at increased risk for multiple sclerosis in later life, suggests research.

Source:

Neurology 2016; Advance online publication

19-10-2016 | Multiple sclerosis | News | Article

Editor's pick

MS drug may reduce not just slow disability symptoms

Alemtuzumab improves pre-existing disability in multiple sclerosis patients rather than just slowing its progression, shows analysis of the CARE-MS II trial.

Source:

Neurology 2016; Advance online publication

03-10-2016 | Multiple sclerosis | News | Article

News in brief

Physical activity fails to halt MS risk

Exercise does not reduce women’s risk of developing multiple sclerosis, an analysis of data on more than 193,000 women shows.

Source:

Neurology 2016; Advance online publication

23-08-2016 | Multiple sclerosis | News | Article

Amiselimod gains MOMENTUM in the treatment of multiple sclerosis

Amiselimod shows potential for the treatment of relapsing–remitting multiple sclerosis, without the cardiac side effects associated with other sphingosine 1-phosphate 1 receptor modulators, phase II study findings show.

Source:

Lancet Neurol 2016; Advance online publication

15-08-2016 | Multiple sclerosis | News | Article

Long-term BENEFIT of early MS treatment confirmed

The 11-year follow-up results of the BENEFIT trial emphasize the importance of initiating treatment early in individuals exhibiting the signs of multiple sclerosis onset, say researchers who observed long-lasting improvements in disease progression and disability.

Source:

Neurology 2016; Advance online publication

18-07-2016 | Multiple sclerosis | News | Article

Editor's pick

Revised MRI criteria improve MS diagnosis accuracy

Researchers believe that, when diagnosing multiple sclerosis, lesions in the symptomatic region should not be excluded, as stated in the McDonald dissemination in space criteria.

Source:

Neurology 2016; Advance online publication

21-06-2016 | Multiple sclerosis | News | Article

Editor's pick

Switch to rituximab shows anti-inflammatory effect in relapsing–remitting MS

Rituximab may be an attractive treatment option for patients with relapsing–remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.

Source:

Neurology 2016; Advance online publication

10-06-2016 | Multiple sclerosis | News | Article

Editor's pick

Immunoablation strengthens haemopoietic stem-cell transplantation effects in MS

Intensifying current transplant conditioning to remove rather than suppress immune cells ahead of autologous haematopoietic stem cell transplantation may result in long-term remission of multiple sclerosis, phase II trial findings show.

Source:

Lancet 2016; Advance online publication

02-06-2016 | Multiple sclerosis | News | Article

HLA genetic risk burden extends to MS outcomes

Human leukocyte antigen alleles not only increase susceptibility to multiple sclerosis, but also influence the course of the disease, suggests research.

Source:

JAMA Neurol 2016; Advance online publication

image credits